Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes
NCT ID: NCT01707134
Last Updated: 2017-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
753 participants
INTERVENTIONAL
1997-09-30
2000-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes
NCT01730014
Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes
NCT01486940
Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes
NCT00571935
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes
NCT02612844
Efficacy and Safety of Insulin Detemir in Type 1 Diabetes
NCT00595374
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
insulin aspart
insulin aspart
Injected subcutaneously (s.c, under the skin) as meal time insulin
insulin NPH
Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
human insulin
human soluble insulin
Injected subcutaneously (s.c, under the skin) as meal time insulin
insulin NPH
Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
insulin aspart
Injected subcutaneously (s.c, under the skin) as meal time insulin
human soluble insulin
Injected subcutaneously (s.c, under the skin) as meal time insulin
insulin NPH
Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR,1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Graz, , Austria
Novo Nordisk Investigational Site
Vienna, , Austria
Novo Nordisk Investigational Site
Vienna, , Austria
Novo Nordisk Investigational Site
Copenhagen, , Denmark
Novo Nordisk Investigational Site
Frederiksberg, , Denmark
Novo Nordisk Investigational Site
Gentofte Municipality, , Denmark
Novo Nordisk Investigational Site
Kolding, , Denmark
Novo Nordisk Investigational Site
Køge, , Denmark
Novo Nordisk Investigational Site
Helsinki, , Finland
Novo Nordisk Investigational Site
Kotka, , Finland
Novo Nordisk Investigational Site
Kuopio, , Finland
Novo Nordisk Investigational Site
Vantaa, , Finland
Novo Nordisk Investigational Site
Bad Neuenahr-Ahrweiler, , Germany
Novo Nordisk Investigational Site
Bad Oeynhausen, , Germany
Novo Nordisk Investigational Site
Bochum, , Germany
Novo Nordisk Investigational Site
Essen, , Germany
Novo Nordisk Investigational Site
Essen, , Germany
Novo Nordisk Investigational Site
Flensburg, , Germany
Novo Nordisk Investigational Site
Frankfurt, , Germany
Novo Nordisk Investigational Site
Freiburg im Breisgau, , Germany
Novo Nordisk Investigational Site
Friedrichsthal, , Germany
Novo Nordisk Investigational Site
Giessen, , Germany
Novo Nordisk Investigational Site
Haan, , Germany
Novo Nordisk Investigational Site
Hamburg, , Germany
Novo Nordisk Investigational Site
Kiel, , Germany
Novo Nordisk Investigational Site
Magdeburg, , Germany
Novo Nordisk Investigational Site
Magdeburg, , Germany
Novo Nordisk Investigational Site
Mainz, , Germany
Novo Nordisk Investigational Site
Mainz, , Germany
Novo Nordisk Investigational Site
Mönchengladbach, , Germany
Novo Nordisk Investigational Site
München, , Germany
Novo Nordisk Investigational Site
Oberhausen, , Germany
Novo Nordisk Investigational Site
Ostercappeln, , Germany
Novo Nordisk Investigational Site
Saarlouis, , Germany
Novo Nordisk Investigational Site
Schwerin, , Germany
Novo Nordisk Investigational Site
Stuttgart, , Germany
Novo Nordisk Investigational Site
Stuttgart, , Germany
Novo Nordisk Investigational Site
Wiesbaden, , Germany
Novo Nordisk Investigational Site
Wuppertal, , Germany
Novo Nordisk Investigational Site
Würzburg, , Germany
Novo Nordisk Investigational Site
Bergen, , Norway
Novo Nordisk Investigational Site
Haugesund, , Norway
Novo Nordisk Investigational Site
Oslo, , Norway
Novo Nordisk Investigational Site
Stavanger, , Norway
Novo Nordisk Investigational Site
Trondheim, , Norway
Novo Nordisk Investigational Site
Falun, , Sweden
Novo Nordisk Investigational Site
Karlstad, , Sweden
Novo Nordisk Investigational Site
Zurich, , Switzerland
Novo Nordisk Investigational Site
Airdrie, , United Kingdom
Novo Nordisk Investigational Site
Bath, , United Kingdom
Novo Nordisk Investigational Site
Blackburn, , United Kingdom
Novo Nordisk Investigational Site
Bolton, , United Kingdom
Novo Nordisk Investigational Site
Church Village, , United Kingdom
Novo Nordisk Investigational Site
Cosham, , United Kingdom
Novo Nordisk Investigational Site
Coventry, , United Kingdom
Novo Nordisk Investigational Site
Edinburgh, , United Kingdom
Novo Nordisk Investigational Site
Edinburgh, , United Kingdom
Novo Nordisk Investigational Site
Exeter, , United Kingdom
Novo Nordisk Investigational Site
Gillingham, , United Kingdom
Novo Nordisk Investigational Site
Hull, , United Kingdom
Novo Nordisk Investigational Site
Inverness, , United Kingdom
Novo Nordisk Investigational Site
Leicester, , United Kingdom
Novo Nordisk Investigational Site
London, , United Kingdom
Novo Nordisk Investigational Site
Middlesbrough, , United Kingdom
Novo Nordisk Investigational Site
Newcastle, , United Kingdom
Novo Nordisk Investigational Site
Northampton, , United Kingdom
Novo Nordisk Investigational Site
Nottingham, , United Kingdom
Novo Nordisk Investigational Site
Penarth, , United Kingdom
Novo Nordisk Investigational Site
Plymouth, , United Kingdom
Novo Nordisk Investigational Site
Reading, , United Kingdom
Novo Nordisk Investigational Site
Rugby, , United Kingdom
Novo Nordisk Investigational Site
Salisbury, , United Kingdom
Novo Nordisk Investigational Site
Sheffield, , United Kingdom
Novo Nordisk Investigational Site
Southampton, , United Kingdom
Novo Nordisk Investigational Site
Stevenage, , United Kingdom
Novo Nordisk Investigational Site
Stirling, , United Kingdom
Novo Nordisk Investigational Site
Swansea, , United Kingdom
Novo Nordisk Investigational Site
Watford, , United Kingdom
Novo Nordisk Investigational Site
Whiston, , United Kingdom
Novo Nordisk Investigational Site
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Res Clin Pract. 2006 Feb;71(2):131-9. doi: 10.1016/j.diabres.2005.05.015. Epub 2005 Jul 27.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANA/DCD/050
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.